{"id":"https://openalex.org/W2089858686","doi":"https://doi.org/10.1097/00004850-199609004-00006","title":"Milnacipran and selective serotonin reuptake inhibitors in major depression","display_name":"Milnacipran and selective serotonin reuptake inhibitors in major depression","alternate_titles":[],"publication_year":1996,"publication_date":"1996-09-01","ids":{"openalex":"https://openalex.org/W2089858686","doi":"https://doi.org/10.1097/00004850-199609004-00006","mag":"2089858686","pmid":"https://pubmed.ncbi.nlm.nih.gov/8923126"},"language":"en","primary_location":{"id":"doi:10.1097/00004850-199609004-00006","doi":"https://doi.org/10.1097/00004850-199609004-00006","is_oa":false,"landing_page_url":"https://doi.org/10.1097/00004850-199609004-00006","pdf_url":null,"source":{"id":"https://openalex.org/S149156103","display_name":"International Clinical Psychopharmacology","issn_l":"0268-1315","issn":["0268-1315","1473-5857"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310318547","host_organization_name":"Wolters Kluwer","host_organization_lineage":["https://openalex.org/P4310318547"],"host_organization_lineage_names":["Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"International Clinical Psychopharmacology","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2089858686"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5111742738","display_name":"J. J. L\u00f3pez-Ibor","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210143394","display_name":"Pierre Fabre (France)","ror":"https://ror.org/04hdhz511","country_code":"FR","type":"company","lineage":["https://openalex.org/I4210143394"]},{"id":"https://openalex.org/I4210164847","display_name":"H\u00f4pital Paul-Brousse","ror":"https://ror.org/05n7yzd13","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I4210097159","https://openalex.org/I4210164847","https://openalex.org/I4405259118"]}],"countries":["FR"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"J. Lopez-Ibor","raw_affiliation_strings":["Neuva Zelanda 44, Madrid, Spain","1Neuva Zelanda 44, E-28034 Madrid, Spain,; 2Universit\u00e9 Paris XI, H\u00f4pital Paul Brousse, 12 Ave P.V. Couturier, 94804 Villejuif, France; 3Institut de Recherche Pierre Fabre, 45 Place Abel Gance, F-92654 Boulogne, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Neuva Zelanda 44, Madrid, Spain","institution_ids":[]},{"raw_affiliation_string":"1Neuva Zelanda 44, E-28034 Madrid, Spain,; 2Universit\u00e9 Paris XI, H\u00f4pital Paul Brousse, 12 Ave P.V. Couturier, 94804 Villejuif, France; 3Institut de Recherche Pierre Fabre, 45 Place Abel Gance, F-92654 Boulogne, France","institution_ids":["https://openalex.org/I4210143394","https://openalex.org/I4210164847"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113664453","display_name":"Julien\u2010Daniel Guelfi","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210143394","display_name":"Pierre Fabre (France)","ror":"https://ror.org/04hdhz511","country_code":"FR","type":"company","lineage":["https://openalex.org/I4210143394"]},{"id":"https://openalex.org/I4210164847","display_name":"H\u00f4pital Paul-Brousse","ror":"https://ror.org/05n7yzd13","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I4210097159","https://openalex.org/I4210164847","https://openalex.org/I4405259118"]}],"countries":["FR"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"J. D. Guelfi","raw_affiliation_strings":["1Neuva Zelanda 44, E-28034 Madrid, Spain,; 2Universit\u00e9 Paris XI, H\u00f4pital Paul Brousse, 12 Ave P.V. Couturier, 94804 Villejuif, France; 3Institut de Recherche Pierre Fabre, 45 Place Abel Gance, F-92654 Boulogne, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Neuva Zelanda 44, E-28034 Madrid, Spain,; 2Universit\u00e9 Paris XI, H\u00f4pital Paul Brousse, 12 Ave P.V. Couturier, 94804 Villejuif, France; 3Institut de Recherche Pierre Fabre, 45 Place Abel Gance, F-92654 Boulogne, France","institution_ids":["https://openalex.org/I4210143394","https://openalex.org/I4210164847"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5027526046","display_name":"Yannick Pl\u00e9tan","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210143394","display_name":"Pierre Fabre (France)","ror":"https://ror.org/04hdhz511","country_code":"FR","type":"company","lineage":["https://openalex.org/I4210143394"]},{"id":"https://openalex.org/I4210164847","display_name":"H\u00f4pital Paul-Brousse","ror":"https://ror.org/05n7yzd13","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I4210097159","https://openalex.org/I4210164847","https://openalex.org/I4405259118"]}],"countries":["FR"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Y. Pletan","raw_affiliation_strings":["1Neuva Zelanda 44, E-28034 Madrid, Spain,; 2Universit\u00e9 Paris XI, H\u00f4pital Paul Brousse, 12 Ave P.V. Couturier, 94804 Villejuif, France; 3Institut de Recherche Pierre Fabre, 45 Place Abel Gance, F-92654 Boulogne, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Neuva Zelanda 44, E-28034 Madrid, Spain,; 2Universit\u00e9 Paris XI, H\u00f4pital Paul Brousse, 12 Ave P.V. Couturier, 94804 Villejuif, France; 3Institut de Recherche Pierre Fabre, 45 Place Abel Gance, F-92654 Boulogne, France","institution_ids":["https://openalex.org/I4210143394","https://openalex.org/I4210164847"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5022131853","display_name":"A. Tournoux","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210143394","display_name":"Pierre Fabre (France)","ror":"https://ror.org/04hdhz511","country_code":"FR","type":"company","lineage":["https://openalex.org/I4210143394"]},{"id":"https://openalex.org/I4210164847","display_name":"H\u00f4pital Paul-Brousse","ror":"https://ror.org/05n7yzd13","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I4210097159","https://openalex.org/I4210164847","https://openalex.org/I4405259118"]}],"countries":["FR"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"A. Tournoux","raw_affiliation_strings":["1Neuva Zelanda 44, E-28034 Madrid, Spain,; 2Universit\u00e9 Paris XI, H\u00f4pital Paul Brousse, 12 Ave P.V. Couturier, 94804 Villejuif, France; 3Institut de Recherche Pierre Fabre, 45 Place Abel Gance, F-92654 Boulogne, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Neuva Zelanda 44, E-28034 Madrid, Spain,; 2Universit\u00e9 Paris XI, H\u00f4pital Paul Brousse, 12 Ave P.V. Couturier, 94804 Villejuif, France; 3Institut de Recherche Pierre Fabre, 45 Place Abel Gance, F-92654 Boulogne, France","institution_ids":["https://openalex.org/I4210143394","https://openalex.org/I4210164847"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5053380833","display_name":"J. F. Prost","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210143394","display_name":"Pierre Fabre (France)","ror":"https://ror.org/04hdhz511","country_code":"FR","type":"company","lineage":["https://openalex.org/I4210143394"]},{"id":"https://openalex.org/I4210164847","display_name":"H\u00f4pital Paul-Brousse","ror":"https://ror.org/05n7yzd13","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I4210097159","https://openalex.org/I4210164847","https://openalex.org/I4405259118"]}],"countries":["FR"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"J. F. Prost","raw_affiliation_strings":["1Neuva Zelanda 44, E-28034 Madrid, Spain,; 2Universit\u00e9 Paris XI, H\u00f4pital Paul Brousse, 12 Ave P.V. Couturier, 94804 Villejuif, France; 3Institut de Recherche Pierre Fabre, 45 Place Abel Gance, F-92654 Boulogne, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Neuva Zelanda 44, E-28034 Madrid, Spain,; 2Universit\u00e9 Paris XI, H\u00f4pital Paul Brousse, 12 Ave P.V. Couturier, 94804 Villejuif, France; 3Institut de Recherche Pierre Fabre, 45 Place Abel Gance, F-92654 Boulogne, France","institution_ids":["https://openalex.org/I4210143394","https://openalex.org/I4210164847"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":4.8739,"has_fulltext":false,"cited_by_count":130,"citation_normalized_percentile":{"value":0.95244361,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":86,"max":99},"biblio":{"volume":"11","issue":null,"first_page":"41","last_page":"46"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11071","display_name":"Treatment of Major Depression","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11071","display_name":"Treatment of Major Depression","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10853","display_name":"Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes","score":0.0,"subfield":{"id":"https://openalex.org/subfields/3205","display_name":"Experimental and Cognitive Psychology"},"field":{"id":"https://openalex.org/fields/32","display_name":"Psychology"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T13118","display_name":"Psychological Treatments and Disorders","score":0.0,"subfield":{"id":"https://openalex.org/subfields/3203","display_name":"Clinical Psychology"},"field":{"id":"https://openalex.org/fields/32","display_name":"Psychology"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/milnacipran","display_name":"milnacipran","score":1.0},{"id":"https://openalex.org/keywords/selective-serotonin-reuptake-inhibitors","display_name":"selective serotonin reuptake inhibitors","score":0.9829999804496765},{"id":"https://openalex.org/keywords/major-depressive-disorder","display_name":"major depressive disorder","score":0.8230000138282776},{"id":"https://openalex.org/keywords/fluoxetine","display_name":"fluoxetine","score":0.9120000004768372},{"id":"https://openalex.org/keywords/fluvoxamine","display_name":"fluvoxamine","score":1.0},{"id":"https://openalex.org/keywords/antidepressant-efficacy","display_name":"antidepressant efficacy","score":0.9179999828338623},{"id":"https://openalex.org/keywords/remission-rate","display_name":"remission rate","score":0.6399999856948853},{"id":"https://openalex.org/keywords/dosing-regimen","display_name":"dosing regimen","score":0.7120000123977661},{"id":"https://openalex.org/keywords/adverse-drug-reactions","display_name":"adverse drug reactions","score":0.7080000042915344},{"id":"https://openalex.org/keywords/pharmacovigilance","display_name":"pharmacovigilance","score":0.7990000247955322},{"id":"https://openalex.org/keywords/tricyclic-antidepressants","display_name":"tricyclic antidepressants","score":0.753000020980835}],"concepts":[{"id":"https://openalex.org/C2780199185","wikidata":"https://www.wikidata.org/wiki/Q421058","display_name":"Milnacipran","level":4,"score":0.9933736324310303},{"id":"https://openalex.org/C2779910183","wikidata":"https://www.wikidata.org/wiki/Q409236","display_name":"Fluvoxamine","level":5,"score":0.8057796955108643},{"id":"https://openalex.org/C2776134451","wikidata":"https://www.wikidata.org/wiki/Q422244","display_name":"Fluoxetine","level":4,"score":0.7863017320632935},{"id":"https://openalex.org/C31487548","wikidata":"https://www.wikidata.org/wiki/Q4859664","display_name":"Reuptake inhibitor","level":4,"score":0.615999162197113},{"id":"https://openalex.org/C2779177272","wikidata":"https://www.wikidata.org/wiki/Q76560","display_name":"Antidepressant","level":3,"score":0.5941960215568542},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.5048220753669739},{"id":"https://openalex.org/C2775864247","wikidata":"https://www.wikidata.org/wiki/Q167934","display_name":"Serotonin","level":3,"score":0.4411133825778961},{"id":"https://openalex.org/C15744967","wikidata":"https://www.wikidata.org/wiki/Q9418","display_name":"Psychology","level":0,"score":0.3890479505062103},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.38317281007766724},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.3120116591453552},{"id":"https://openalex.org/C118552586","wikidata":"https://www.wikidata.org/wiki/Q7867","display_name":"Psychiatry","level":1,"score":0.25274860858917236},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.0715508759021759},{"id":"https://openalex.org/C558461103","wikidata":"https://www.wikidata.org/wiki/Q154430","display_name":"Anxiety","level":2,"score":0.057431161403656006}],"mesh":[{"descriptor_ui":"D000078764","descriptor_name":"Milnacipran","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000928","descriptor_name":"Antidepressive Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000928","descriptor_name":"Antidepressive Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D002986","descriptor_name":"Clinical Trials as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D003521","descriptor_name":"Cyclopropanes","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D003521","descriptor_name":"Cyclopropanes","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D003866","descriptor_name":"Depressive Disorder","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D006261","descriptor_name":"Headache","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009325","descriptor_name":"Nausea","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":false},{"descriptor_ui":"D011569","descriptor_name":"Psychiatric Status Rating Scales","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017367","descriptor_name":"Selective Serotonin Reuptake Inhibitors","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D017367","descriptor_name":"Selective Serotonin Reuptake Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D018759","descriptor_name":"Adrenergic Uptake Inhibitors","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D018759","descriptor_name":"Adrenergic Uptake Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.1097/00004850-199609004-00006","doi":"https://doi.org/10.1097/00004850-199609004-00006","is_oa":false,"landing_page_url":"https://doi.org/10.1097/00004850-199609004-00006","pdf_url":null,"source":{"id":"https://openalex.org/S149156103","display_name":"International Clinical Psychopharmacology","issn_l":"0268-1315","issn":["0268-1315","1473-5857"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310318547","host_organization_name":"Wolters Kluwer","host_organization_lineage":["https://openalex.org/P4310318547"],"host_organization_lineage_names":["Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"International Clinical Psychopharmacology","raw_type":"journal-article"},{"id":"pmid:8923126","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/8923126","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"International clinical psychopharmacology","raw_type":"Comparative Study"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9907000064849854,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W1986437549","https://openalex.org/W1977768874","https://openalex.org/W2059515744","https://openalex.org/W165868506","https://openalex.org/W1982214874","https://openalex.org/W1994371881","https://openalex.org/W2013781911","https://openalex.org/W2036084056","https://openalex.org/W1988934432","https://openalex.org/W2084271334"],"abstract_inverted_index":{"In":[0,189],"drug":[1],"development":[2],"the":[3,18,21,27,35,39,45,59,82,103,108,116,203,205,244,300],"move":[4],"from":[5,224],"tricyclic":[6],"antidepressants":[7],"(TCAs)":[8],"to":[9,37,54,80,213,217,284,294],"selective":[10,71],"serotonin":[11,72],"reuptake":[12,40,75],"inhibitors":[13,76],"(SSRIs)":[14],"involved":[15],"not":[16],"only":[17],"loss":[19],"of":[20,31,41,66,70,115,125,133,167,174,266,274],"direct":[22],"receptor":[23],"interactions":[24],"responsible":[25],"for":[26,44,93],"adverse":[28],"side":[29,250],"effects":[30],"TCAs,":[32,60],"but":[33],"also":[34,179],"ability":[36],"inhibit":[38],"noradrenaline.":[42],"Selectivity":[43],"single":[46],"neurotransmitter,":[47],"serotonin,":[48],"may":[49],"explain":[50],"why":[51],"SSRIs":[52,109,185,285],"tend":[53],"be":[55,214],"less":[56,256],"efficacious":[57],"than":[58,144,183],"especially":[61],"in":[62,130,192,202,232,282],"more":[63],"serious":[64],"forms":[65],"depression.":[67],"The":[68,272],"advent":[69],"and":[73,111,255,270,286],"noradrenaline":[74],"(SNRIs)":[77],"has":[78],"tended":[79],"confirm":[81],"idea":[83],"that":[84,278],"an":[85,218],"action":[86],"on":[87],"both":[88],"monoamine":[89],"systems":[90],"is":[91,280,287],"important":[92],"maximal":[94],"antidepressant":[95],"efficacy.":[96],"This":[97],"paper":[98],"reviews":[99],"clinical":[100,233],"trials":[101,118,234],"comparing":[102],"new":[104],"SNRI":[105],"milnacipran":[106,138,182,196,220,236,246,279],"with":[107,127,137,145,169,181,184,210,235,243,262],"fluoxetine":[110,146,211],"fluvoxamine.":[112],"A":[113],"meta-analysis":[114],"principal":[117],"shows":[119],"greater":[120],"response":[121,207],"rates":[122,164],"(the":[123,165],"proportion":[124,166],"patients":[126,168,230],"a":[128,142,150,157,200,225,263,296],"decrease":[129],"symptom":[131],"scores":[132],"50%":[134],"or":[135,152,176],"more)":[136],"(50":[139],"mg":[140,148,155,195],"twice":[141,156],"day)":[143,158],"(20":[147],"once":[149,199],"day),":[151],"fluvoxamine":[153],"(100":[154],"(milnacipran:":[159],"64%;":[160],"SSRIs:":[161],"50%).":[162],"Remission":[163],"Hamilton":[170],"Depression":[171],"Rating":[172],"Scores":[173],"7":[175],"below)":[177],"were":[178],"higher":[180,206,264],"(39":[186],"versus":[187],"28%).":[188],"one":[190],"study,":[191],"which":[193],"100":[194],"was":[197],"given":[198],"day":[201],"evening,":[204],"rate":[208],"obtained":[209],"appears":[212,293],"largely":[215],"attributable":[216],"inappropriate":[219],"dosage":[221],"regimen.":[222],"Data":[223],"pharmacovigilance":[226],"database":[227],"including":[228],"all":[229],"participating":[231],"(n":[237],"=":[238],"5732)":[239],"showed":[240],"that,":[241],"compared":[242],"SSRIs,":[245],"produced":[247],"fewer":[248],"gastrointestinal":[249],"effects,":[251],"such":[252],"as":[253],"nausea,":[254],"anxiety.":[257],"Milnacipran":[258],"was,":[259],"however,":[260],"associated":[261],"incidence":[265],"headache,":[267],"dry":[268],"mouth":[269],"dysuria.":[271],"results":[273],"these":[275],"studies":[276],"suggest":[277],"superior":[281],"efficacy":[283],"equally":[288],"well":[289],"tolerated.":[290],"Milnacipran,":[291],"therefore,":[292],"offer":[295],"therapeutic":[297],"advantage":[298],"over":[299],"SSRIs.":[301]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2089858686","counts_by_year":[{"year":2025,"cited_by_count":2},{"year":2024,"cited_by_count":2},{"year":2022,"cited_by_count":3},{"year":2021,"cited_by_count":1},{"year":2020,"cited_by_count":1},{"year":2019,"cited_by_count":2},{"year":2018,"cited_by_count":4},{"year":2016,"cited_by_count":2},{"year":2015,"cited_by_count":2},{"year":2014,"cited_by_count":1},{"year":2013,"cited_by_count":10},{"year":2012,"cited_by_count":3}],"updated_date":"2026-11-16T12:05:36.265796","created_date":"2016-06-24T00:00:00"}
